Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
IR

NASDAQ · IRON

Disc Medicine, Inc.

Healthcare · Biotechnology

$78.62

Down-$2.22 (-2.75%)

Updated Nov 3, 2026, 4:22 AM

SID Score

5.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.53B
P/E ratio
-18.17
Dividend yield
0.00%
52-week range
$40.00 – $99.50
Volume
525.8K
Avg. volume
503.23K

Price performance · IRON

IRON price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

IRON closed at $78.62 after 21 trading sessions, up 24.14% for the selected period.

Last close
$78.62
Period change
+24.14%
Period low
$55.74
Period high
$83.20
Daily close
View OHLC price history
IRON OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$80.99$81.69$78.04$78.62525.8K
Oct 30, 2026$82.79$83.03$78.61$80.84684.98K
Oct 29, 2026$83.51$85.00$82.22$82.84688.36K
Oct 28, 2026$78.88$83.635$78.88$83.201.1M
Oct 27, 2026$77.23$80.50$76.50$79.901.47M
Oct 26, 2026$74.80$78.025$74.80$77.661.22M
Oct 23, 2026$74.29$75.555$74.005$74.511.96M
Oct 22, 2026$75.25$78.00$74.77$75.031.59M
Oct 21, 2026$77.80$81.50$75.89$76.004.64M
Oct 20, 2026$79.21$80.00$74.52$79.482.21M
Oct 19, 2026$72.70$80.22$69.98$78.938.49M
Oct 16, 2026$56.56$57.235$55.00$56.84569.54K
Oct 15, 2026$56.66$58.085$55.95$56.65699.76K
Oct 14, 2026$56.21$58.835$55.48$55.74430.72K
Oct 13, 2026$60.16$60.48$56.47$56.60603.47K
Oct 12, 2026$62.20$62.76$60.355$60.48657.22K
Oct 9, 2026$60.67$63.50$60.03$62.06691.14K
Oct 8, 2026$60.71$61.58$58.22$60.77846.82K
Oct 7, 2026$61.20$62.97$60.02$61.18562.93K
Oct 6, 2026$63.70$64.66$61.31$61.651.42M
Oct 5, 2026$65.13$65.565$63.01$63.33456.32K

Latest IRON news

The latest Smart Investors Daily articles mentioning IRON.

Stock researchCompany · Overview

IRON research

Overview

Company profile and research snapshot.

Company profile

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$123.50
Implied upside
—
Analysts
—
IRON recent ratings
DateFirmRatingTarget
Oct 20, 2026Wells FargoOverweight—
Oct 20, 2026WedbushOutperform—
Oct 20, 2026Truist SecuritiesBuy—
Oct 20, 2026Morgan StanleyOverweight—
Oct 19, 2026BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 2, 2026

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that company management will participate in fireside chats at upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9th at 10:30 a.m. ETStifel 2026 Healthcare Conf

Yahoo · Oct 21, 2026

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. Disc is selling 6,000,000 shares of common stock at a public offering price of $75.00 per share. In addition, Disc has gr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By